VISUAL ABSTRACTYoshida
Electrical VNS is known to restore autonomic balance and improve heart failure.
This study aimed to elucidate the therapeutic effects of VNS on severe PAH in a rat model. 
SUMMARY
This study aimed to elucidate the therapeutic effects of electrical vagal nerve stimulation (VNS) on severe pulmonary arterial hypertension in a rat model. In a pathophysiological study, VNS significantly restored autonomic balance, decreased mean pulmonary arterial pressure, attenuated pulmonary vascular remodeling, and preserved right ventricular function. In a survival study, VNS significantly improved the survival rate in both the prevention (VNS from 0 to 5 weeks after a SU5416 injection) and treatment (VNS from 5 to 10 weeks) protocols. Thus, VNS may serve as a novel therapeutic strategy for pulmonary arterial hypertension. PAH disrupts autonomic balance by deactivating the parasympathetic nervous system (4) and activating the sympathetic nervous system (5) . Previous reports indicated that autonomic imbalance predicts a high mortality of PAH (6) . Furthermore, Carver et al. (7) reported that vagotomy of the pulmonary region in rats leads to fibrosis in both pulmonary arteries (PAs) and airways. Therefore, autonomic function may play an important role in structural homeostasis in PAs. Recently, sympathoinhibitory therapies such as PA denervation (8, 9) and renal denervation (10) have been shown to reduce pulmonary vascular remodeling and PVR.
In addition, a growing body of evidence is accumulating both on the benefits (11, 12) and disadvantages (13) of beta-blocker therapy for PAH.
However, it remains unknown how direct activation of the parasympathetic nervous system affects PAH.
Vagal nerve stimulation (VNS) is a device therapy
that directly and electrically activates the parasympathetic nerve. In animal experiments, VNS has shown significant therapeutic benefits for various cardiovascular diseases, including myocardial infarction (14) , fatal arrhythmia (15) , and chronic heart failure (16) . VNS has been used in patients with heart failure (17) and epilepsy (18) . Although clinical trials have shown the safety of VNS, the efficacy of VNS for heart failure remains controversial (19) .
In the present study, we examined how VNS affects autonomic function, hemodynamic variables, pulmonary histopathology, and survival in the SU5416/ hypoxia/normoxia model of PAH using Fischer 344 rats, a model that reproduces essential histopathological features of severe PAH, including catastrophic prognosis in humans (20, 21) . We used 10-week-old male Fischer 344 rats (Japan SLC, Hamamatsu, Japan) (n ¼ 102). All rats were housed in a room maintained at constant temperature (25 AE 2 C) and 12-h light/dark cycle, and given water ad libitum during the entire experiment. To induce PAH, rats weighing 180 to 200 g were given a subcutaneous injection of SU5416 (204005-46-9, Tocris
Bioscience, Bristol, United Kingdom; 20 mg/kg) followed by exposure to hypoxia (10% oxygen) for 3 weeks and then returned to normoxic conditions, according to previous reports (20, 21) .
First, the effects of chronic VNS on PAH in freemoving rats were evaluated. We then analyzed the direct effects of acute VNS on advanced PAH in anesthetized rats. To administer chronic VNS, we Survival study. The effects of chronic VNS on survival of PAH rats (n ¼ 54) were examined. Rats that underwent 5-week VNS 0 week (-5 week in Figure 2) after SU5416 injection (prevention group, n ¼ 14)
were compared with SS rats (SS group, n ¼ 26). We also examined the survival of rats that underwent 5-week VNS from 5 weeks (0 week in Figure 2 ) after SU5416 injection (treatment group, n ¼ 14). The intensity of VNS was titrated at 0 and 3 weeks after VNS initiation in both the prevention and treatment protocols. We observed survival of all rats for 10 weeks from 5 weeks (0 week in Figure 2 ) after SU5416 injection. Rats in protocol 1B were different from those in protocol 1A.
P r o t o c o l 2 : e f f e c t s o f a c u t e V N S o n e s t a b l i s h e d P A H i n a n e s t h e t i z e d r a t s . York) was placed in the aortic root for measurements STATISTICAL ANALYSIS. In protocol 1A, differences among the 3 groups were tested by using 1-way analysis of variance, followed by post hoc TukeyKramer tests. Post hoc comparisons were conducted if a significant result was obtained in the overall analysis of variance. In protocol 1B, survival was estimated by using the Kaplan-Meier method and analyzed by using the log-rank test among the SSprevention, SS-treatment, and prevention-treatment groups. In protocol 2, differences between prestimulation and post-stimulation data were tested by using paired Student's t-tests, and differences in gene and protein assays between SS and VNS were tested by using Student's t-test. Statistical analyses
FIGURE 1 Photographic Images of Vagal Nerve Stimulation in Rats
Electrodes are (A) attached to the right cervical vagal nerve and (B) connected to a neurostimulator (C) implanted subcutaneously in the back of a rat.
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were performed by using JMP Pro 11 (SAS Institute, Inc., Cary, North Carolina). Values are given as mean AE SEM. Differences were considered significant when p values were <0.05.
RESULTS EFFECTS OF CHRONIC VNS ON AUTONOMIC FUNCTION.
All rats survived until 5 weeks after SU5416 injection in protocol 1A. Representative traces of power spectral density of HRV are shown in Figure 3A . HRV and plasma NE data are summarized in Table 1 . Compared with SS, VNS increased the high-frequency component and tended to decrease the low-frequency/high-frequency ratio, indicating improvement of autonomic balance.
This outcome is supported by the finding that VNS markedly decreased plasma NE levels, indicating the suppression of sympatho-excitation. other abbreviations as in Figure 2 .
EFFECTS OF CHRONIC VNS ON HEART WEIGHT AND ECHOCARDIOGRAPHIC FINDINGS. As shown in
Yoshida et al. ( Figure 9F ). In addition, VNS up-regulated Alpha7-nachr, which is known as a receptor that modulates anti-inflammatory responses in VNS (p < 0.05) ( Figure 9H ).
DISCUSSION
The goal of the present study was to investigate the therapeutic effects of VNS in rats with PAH and to explore novel therapeutic strategies for PAH. We 
EFFECT OF CHRONIC VNS ON AUTONOMIC BALANCE.
Autonomic imbalance in PAH (4,5) predicts a high mortality (6) . As shown in Table 1 , chronic VNS increased the high-frequency component of HRV and Other abbreviations as in Figure 2 .
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decreased plasma NE levels in rats with PAH. These data indicate that autonomic balance in the rats with SU5416/hypoxia/normoxia model-induced PAH was restored by VNS.
VNS directly activates the parasympathetic nervous system. In the present study, chronic VNS significantly increased the high-frequency component of HRV, indicating restoration of normal parasympathetic activity. VNS also reduced plasma NE levels. We have previously reported that VNS inhibits sympathetic nerve activity by stimulating the afferent pathway (25). However, we cannot directly extrapolate our previous finding to the present study because we stimulated the vagal nerve at a low intensity that did not reduce either heart rate or AP. (12) reported that beta-blocker therapy did not ameliorate pulmonary vascular remodeling or reduce PAP.
Therefore, whether sympatho-inhibition improves PAH remains controversial.
In the present study, chronic VNS significantly lowered PAP and PVR (Figure 3 ) with a reduction of RV function is tightly linked to poor prognosis of PAH (3). In this study, chronic VNS significantly increased Max þdP/dt/RVEDP and decreased RVEDP, while increasing the cardiac index (Figure 3) , indicating the improvement of RV function. We also showed that VNS attenuated fibrosis, decreased apoptosis of cardiomyocytes, and increased capillary density in the right ventricle ( Figure 5) . Li et al. (16) showed that VNS improved left ventricular function and survival in rats with post-myocardial infarction heart failure. Following their study, several investigators reported that VNS exerts anti-apoptotic Five-week VNS markedly improved survival both in the prevention (red, n ¼ 14; p < 0.01) and treatment (purple, n ¼ 14; p < 0.05) groups compared with the SS (blue, n ¼ 25) group, with relative risk reductions of 53.0% and 34.2%, respectively. The survival assessment was started from 5 weeks after SU5416 injection. Prevention, 5-week VNS initiated from 0 weeks after SU5416 injection; treatment, 5-week VNS initiated from 5 weeks after SU5416 injection (0 weeks in Figure 7 ). Differences were tested by using the Kaplan-Meier method with log-rank testing among the SS-prevention, SS-treatment, and prevention-treatment groups. *p < 0.05 and **p < 0.01 vs. SS. n.s. ¼ not significant; other abbreviations as in Figure 2 .
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and anti-fibrotic effects (27, 28) . In addition, it is well established that sympatho-inhibition by betablocker therapy reduces fibrosis and apoptosis, and increases capillary density in the right ventricle via anti-inflammatory effects (11, 12) . On the basis of these previous studies, our results suggest that VNS may have a direct beneficial effect on RV function in rats with severe PAH. Conversely, reduction of PAP could Vagal Nerve Stimulation for PAH account for the improvement in RV function (29) . In this study, we also showed that VNS reduced PVR and PAP. Thus, we cannot differentiate between direct and indirect beneficial effects of VNS on RV function.
The impact of chronic VNS on survival in this study is the most critical finding for clinical translation. As shown in Figure 7 , VNS markedly improved survival both in the prevention and the treatment protocols.
In the treatment protocol, despite initiating VNS after In patients with severe PAH, perivascular macrophages are increased in PA (30) . The activation of macrophage releases inflammatory cytokines such as In the present study, VNS significantly reduced perivascular macrophage infiltration ( Figure 4C ) and down-regulated pro-inflammatory cytokines IL-6, IL1b, and MCP-1 in the lung ( Figure 6 ). In addition, acute VNS down-regulated mRNA expression of Tnfa and up-regulated Alpha7nachr (Figure 9 ). Combining our current data with previous findings, we speculate that chronic VNS induces general suppression of inflammatory responses, improves PA cell proliferation/ apoptosis imbalance, and attenuates pulmonary vascular remodeling.
It is well known that VNS releases acetylcholine and induces local NO production in heart and systemic arteries (28, 36) and that the increase in NO lowers PVR in PAH (37) . However, acute VNS did not change eNOS and phosphorylated eNOS protein levels or pulmonary vascular characteristics ( Figure 9 ).
Although we did not measure endogenous NO production, these data suggest that acute VNS exerts no direct effect on pulmonary vasoconstriction in rats with PAH, at least in the present stimulation settings.
STUDY LIMITATIONS. This study is the first report, to the best of our knowledge, to show the major therapeutic effects of electrical VNS on PAH model rats.
Because an implantable device for VNS has already been applied clinically, and its safety and feasibility 
